Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00293111
Status:
TERMINATED
Last Update Posted:
2014-05-12
First Post:
2006-02-16
Brief Title:
Safety and Efficacy of SDX-101 R-Etodolac in Patients With Relapsed or Refractory Multiple Myeloma MM
Sponsor:
Cephalon
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
An Open Label Multi-Center Phase II Study to Investigate the Safety and Efficacy of SDX-101 R-Etodolac in Patients With Relapsed or Refractory Multiple Myeloma MM
Status:
TERMINATED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An Open Label Multi-Center Phase II Study to Investigate the Safety and Efficacy of SDX-101 R-Etodolac in Patients with Relapsed or Refractory Multiple Myeloma MM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None